TRB-001
/ Tridem Bioscience
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 25, 2026
Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Tridem Bioscience FlexCo
New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT
1 to 1
Of
1
Go to page
1